These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598 [TBL] [Abstract][Full Text] [Related]
5. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532 [TBL] [Abstract][Full Text] [Related]
6. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report. Lemm D; Muegge LO; Hoeffken K; Aklan T; Mentzel T; Thorwarth M; Schultze-Mosgau S Oral Maxillofac Surg; 2008 Dec; 12(4):209-13. PubMed ID: 18751744 [TBL] [Abstract][Full Text] [Related]
7. Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas. Koseła-Paterczyk H; Rutkowski P Expert Rev Anticancer Ther; 2017 Dec; 17(12):1107-1116. PubMed ID: 28988501 [TBL] [Abstract][Full Text] [Related]
8. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation. Rutkowski P; Klimczak A; Ługowska I; Jagielska B; Wągrodzki M; Dębiec-Rychter M; Pieńkowska-Grela B; Świtaj T Eur J Surg Oncol; 2017 Jun; 43(6):1134-1141. PubMed ID: 28365129 [TBL] [Abstract][Full Text] [Related]
9. [New molecular approaches in dermatofibrosarcoma protuberans]. Kaya G Rev Med Suisse; 2009 Jul; 5(211):1519-24. PubMed ID: 19694363 [TBL] [Abstract][Full Text] [Related]
10. Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results. Malhotra B; Schuetze SM Curr Opin Oncol; 2012 Jul; 24(4):419-24. PubMed ID: 22510939 [TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Kérob D; Porcher R; Vérola O; Dalle S; Maubec E; Aubin F; D'Incan M; Bodokh I; Boulinguez S; Madelaine-Chambrin I; Mathieu-Boue A; Servant JM; de Kerviler E; Janin A; Calvo F; Pedeutour F; Lebbe C Clin Cancer Res; 2010 Jun; 16(12):3288-95. PubMed ID: 20439456 [TBL] [Abstract][Full Text] [Related]
12. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Shimizu A; O'Brien KP; Sjöblom T; Pietras K; Buchdunger E; Collins VP; Heldin CH; Dumanski JP; Ostman A Cancer Res; 1999 Aug; 59(15):3719-23. PubMed ID: 10446987 [TBL] [Abstract][Full Text] [Related]
13. Current treatment options in dermatofibrosarcoma protuberans. Lemm D; Mügge LO; Mentzel T; Höffken K J Cancer Res Clin Oncol; 2009 May; 135(5):653-65. PubMed ID: 19205737 [TBL] [Abstract][Full Text] [Related]
14. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients. Wang C; Luo Z; Chen J; Zheng B; Zhang R; Chen Y; Shi Y Medicine (Baltimore); 2015 May; 94(17):e773. PubMed ID: 25929918 [TBL] [Abstract][Full Text] [Related]
15. Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses. Johnson-Jahangir H; Sherman W; Ratner D J Natl Compr Canc Netw; 2010 Aug; 8(8):881-5. PubMed ID: 20870634 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up. Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542 [TBL] [Abstract][Full Text] [Related]
17. Transformed dermatofibrosarcoma protuberans: real time polymerase chain reaction detection of COL1A1-PDGFB fusion transcripts in sarcomatous areas. Szollosi Z; Scholtz B; Egervari K; Nemes Z J Clin Pathol; 2007 Feb; 60(2):190-4. PubMed ID: 16731589 [TBL] [Abstract][Full Text] [Related]
18. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. Rubin BP; Schuetze SM; Eary JF; Norwood TH; Mirza S; Conrad EU; Bruckner JD J Clin Oncol; 2002 Sep; 20(17):3586-91. PubMed ID: 12202658 [TBL] [Abstract][Full Text] [Related]
19. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Sjöblom T; Shimizu A; O'Brien KP; Pietras K; Dal Cin P; Buchdunger E; Dumanski JP; Ostman A; Heldin CH Cancer Res; 2001 Aug; 61(15):5778-83. PubMed ID: 11479215 [TBL] [Abstract][Full Text] [Related]